Ordering
Available Variants25 mg
CHA.51412-25mg
Price
€74.96
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
25 mg | CHA.51412-25mg | €74.96 |
VETRANAL®, analytical standard
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C18H15ClN2O2S |
|---|---|
| CAS Number | 202409-33-4 |
| Molecular Weight | 358.84 |
| UNSPSC Code | 41116107 |
| NACRES | NA.24 |
| PubChem Substance ID | 329753738 |
| MDL number | MFCD06797512 |
| Beilstein/REAXYS Number | 8073797 |
Safety Information Handling visibility
| pictograms |
GHS06
 GHS06
|
|---|---|
| signalword | Danger |
| hcodes | H302,H310 |
| pcodes | P262 - P264 - P270 - P280 - P301 + P312 - P302 + P352 + P310 |
| Hazard Classifications | Acute Tox. 2 Dermal - Acute Tox. 4 Oral |
| Storage Class | 6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials |
| wgk | WGK 3 |
Technical Overview & Applications Use-case context
Etoricoxib, with a chemical identifier of CAS 202409-33-4, is a selective cyclooxygenase-2 (COX-2) inhibitor primarily used in the management of pain and inflammation associated with various conditions, including osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. Its mechanism of action involves the selective inhibition of COX-2, an enzyme responsible for the production of prostaglandins, which are key mediators of inflammation and pain. By inhibiting COX-2, etoricoxib reduces the production of these pro-inflammatory prostaglandins, thereby exerting its therapeutic effects. Etoricoxib has been shown to be effective in reducing symptoms of arthritis, such as pain and stiffness, and improving functional ability, with a favorable gastrointestinal safety profile compared to non-selective NSAIDs. It is generally well-tolerated, although common side effects may include hypertension, edema, and gastrointestinal disturbances.
